Pacer Advisors Inc. Raises Stock Position in Medpace Holdings, Inc. $MEDP

Pacer Advisors Inc. boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 38.1% in the fourth quarter, HoldingsChannel reports. The firm owned 153,652 shares of the company’s stock after buying an additional 42,362 shares during the period. Pacer Advisors Inc.’s holdings in Medpace were worth $86,299,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its holdings in Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after acquiring an additional 324,293 shares during the period. Wasatch Advisors LP raised its position in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after acquiring an additional 24,625 shares during the period. Invesco Ltd. lifted its holdings in Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after acquiring an additional 85,517 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in Medpace by 19.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock worth $210,637,000 after purchasing an additional 60,883 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 20.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. BMO Capital Markets dropped their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Royal Bank Of Canada decreased their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Barclays lowered their price target on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a report on Friday, April 24th. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Finally, Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Medpace currently has a consensus rating of “Hold” and a consensus price target of $467.08.

Medpace Price Performance

Medpace stock opened at $460.20 on Friday. The stock has a market capitalization of $13.14 billion, a PE ratio of 28.93, a price-to-earnings-growth ratio of 2.32 and a beta of 1.18. Medpace Holdings, Inc. has a 12 month low of $301.90 and a 12 month high of $628.92. The business has a 50 day simple moving average of $453.33 and a 200-day simple moving average of $499.77.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. During the same period in the prior year, the company posted $3.67 EPS. The business’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.